Quick answer
What is GLP-1?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
GLP-1 is a peptide, grouped on this site under Incretin receptor agonists, and the 12 research records kept here are 6 from studies in rats or mice, 1 from a trial in people and 5 that do not state what kind of study it is.
The literature search returned 25,817 records. This site keeps 12 of them, which is 0.05 per cent of what came back.
What it is
This site puts it in the Incretin receptor agonists group.
The endogenous ligand of the GLP-1 receptor, reported in the retrieved records as a physiological incretin with a central role in the regulation of feeding.[1, 2]
Stated in the titles of the cited 1987 Lancet and 1996 Nature papers.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 1 interventional human trial record among 12 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 25,805 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet (London, England) (1987). pmid:2890903
- A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (1996). pmid:8538742